ALKINDI SPRINKLE Drug Patent Profile

When do Alkindi Sprinkle patents expire, and when can generic versions of Alkindi Sprinkle launch?

Alkindi Sprinkle is a drug marketed by Eton and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-six patent family members in twenty-five countries.

The generic ingredient in ALKINDI SPRINKLE is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alkindi Sprinkle

A generic version of ALKINDI SPRINKLE was approved as hydrocortisone by IMPAX LABS INC on March 30^th, 2007.

Summary for ALKINDI SPRINKLE

International Patents:	56
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ALKINDI SPRINKLE

ALKINDI SPRINKLE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-001	Sep 29, 2020		RX	Yes	No
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-003	Sep 29, 2020		RX	Yes	No
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-002	Sep 29, 2020		RX	Yes	No
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-004	Sep 29, 2020		RX	Yes	Yes
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-003	Sep 29, 2020		RX	Yes	No			Y
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-001	Sep 29, 2020		RX	Yes	No
Eton	ALKINDI SPRINKLE	hydrocortisone	GRANULE;ORAL	213876-001	Sep 29, 2020		RX	Yes	No			Y

International Patents for ALKINDI SPRINKLE

See the table below for patents covering ALKINDI SPRINKLE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2909060	COMPOSITION COMPRENANT DE L'HYDROCORTISONE (COMPOSITION COMPRISING HYDROCORTISONE)
European Patent Office	2780003	TRAITEMENT DE L'INSUFFISANCE SURRÉNALE (TREATMENT OF ADRENAL INSUFFICIENCY)
Japan	2014533679	副腎機能障害の治療
Russian Federation	2664678	Композиция, содержащая гидрокортизон (COMPOSITION COMPRISING HYDROCORTISONE)
Hong Kong	1214131	包含氫化可的松的組合物 (COMPOSITION COMPRISING HYDROCORTISONE)
South Africa	201507210	COMPOSITION COMPRISING HYDROCORTISONE
Japan	6371379

Supplementary Protection Certificates for ALKINDI SPRINKLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0809498	SPC/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498	10C0038	France		PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026

ALKINDI SPRINKLE (Synthetic Hydrocortisone Oral Suspension) Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is ALKINDI SPRINKLE and where does it sit in the treatment landscape?

ALKINDI SPRINKLE is an oral formulation of hydrocortisone (corticosteroid) for the treatment of adrenal insufficiency in pediatric patients (including congenital adrenal hyperplasia, and other indications under the approved label). The product line is marketed as a sprinkle formulation intended to support pediatric administration, with the active ingredient and therapeutic class anchored in systemic glucocorticoid replacement.

From an investment standpoint, ALKINDI SPRINKLE’s fundamentals are driven less by “novel molecule” dynamics and more by:

• pediatric chronic-use durability,
• payer coverage and formulary placement across a small, high-acuity population,
• competitive pressure from other hydrocortisone products and steroid regimens,
• margin structure tied to supply chain and pediatric-friendly formulation economics.

What is the core “fundamental” value driver for investors?

For hydrocortisone replacement therapies in pediatrics, the dominant value drivers tend to be commercial stability rather than rapid peak-to-shelf-market scaling:

1. Chronic utilization pattern

   • Patients remain on therapy long-term, supporting sustained demand when coverage is stable.

2. Switching friction

   • Pediatric dosing and caregiver handling can create inertia, which typically favors formulations that reduce administration barriers.

3. Payer dynamics

   • Coverage frequently hinges on diagnosis code, age, and whether the product is aligned with guideline-based regimens.
   • Prior authorization and step edits can delay uptake but then support stickiness once established.

4. Manufacturing and supply continuity

   • Steroid supply disruptions matter because the therapy is replacement-level; outages can lead to temporary substitutions, but rehabbing the line after a disruption can take time.

What is the competitive set and how does it affect pricing power?

ALKINDI SPRINKLE competes within hydrocortisone replacement and pediatric adrenal insufficiency management. The main competitive forces generally include:

• other hydrocortisone oral formulations (tablets, suspensions, compounded or branded competitors depending on market),
• alternative steroid regimens for congenital adrenal hyperplasia (CAH) and adrenal insufficiency management, depending on guideline adoption and clinician preference.

Investment implication: pricing power is more limited than for targeted oncology drugs. Competitive advantage is more likely to manifest through:

• coverage wins at the formulation level,
• improved adherence and reduced caregiver friction,
• fewer real-world dosing errors versus less flexible pediatric presentations.

Where is ALKINDI SPRINKLE in the product lifecycle and what does that mean for risk?

Because ALKINDI SPRINKLE is a formulation of a known drug class (hydrocortisone), lifecycle risk clusters around:

• patent clock and exclusivity windows tied to formulation, method-of-use, and pediatric labeling,
• segment erosion if generic or alternative formulations gain formulary access,
• regulatory or label expansions that can extend duration of relevance.

Commercial risk profile typical for pediatric chronic steroids:

• Lower clinical trial volatility than breakthrough therapeutics
• Higher dependency on payer access and supply continuity
• Moderate long-term erosion risk if exclusivity ends and generics gain adoption

What are the likely financial and operating fundamentals to underwrite?

Investors underwriting ALKINDI SPRINKLE generally focus on the following measurable levers:

Demand and uptake metrics

• new pediatric starts (driven by pediatric endocrinology visits and diagnosis identification),
• treatment persistence and refill rates (replacement therapy)
• net revenue retention (payer coverage stability, dose migration)

Pricing and access

• WAC-to-net discounts trend (rebates, copays, managed entry)
• formulary placement (commercial vs government coverage)
• prior authorization outcomes and time-to-approval patterns

Supply and manufacturing

• stability of supply volumes
• batch yield and quality controls for oral suspension/sprinkle formats
• cost of goods impact from formulation complexity

Product adjacency risk

• shift toward alternative hydrocortisone presentations or compounded regimens during pricing pressure
• patient migration to other branded competitors if formulary changes

What does the investment scenario look like under base, bull, and bear cases?

The scenario framework below maps to how investors typically model chronic pediatric products where molecule risk is limited, but coverage and exclusivity are material.

Base case (coverage holds, moderate growth)

• Uptake continues in pediatric endocrinology networks.
• Formulary position remains stable with incremental share gains via clinician familiarity.
• Net price pressure exists but does not force widespread switching.

Primary downside risks: loss of formulary access in specific payers, stronger-than-expected generic competition after exclusivity.

Bull case (accelerated share and improved access)

• Wider formulary acceptance and reduced administrative friction.
• Prescriber preference grows due to caregiver handling and dosing accuracy.
• Label expansion or better diagnostic capture increases the addressable population in practice.

Primary upside levers: payer wins, Medicaid/govt coverage alignment, durable persistence.

Bear case (coverage erosion and competitive switching)

• Increased generic penetration or therapeutic substitution reduces share.
• Higher rebate and copay pressure compresses net revenue per patient.
• Supply constraints force temporary switching and slow rehospitalization/rehabbing.

Primary downside risks: discontinuation of supply interruptions, payer restrictions or restrictive step edits.

What milestones and signals matter most over the next 12–36 months?

For an investment calendar, track indicators that move the product’s realized revenue:

1. Formulary and payer wins/losses

   • changes in commercial and government formularies
   • trends in prior authorization approval rates

2. Revenue trajectory vs prescription trends

   • prescriptions or patient starts outpacing revenue can indicate pricing pressure
   • revenue outpacing prescriptions can indicate improved net pricing or dose intensity

3. Competitive entry timing

   • credible timelines for generic hydrocortisone oral options and formulation-specific competition
   • shifts in copay assistance utilization and payer restrictions

4. Supply and quality stability

   • recalls, hold-and-release events, or chronic allocation patterns

5. Regulatory movement

   • label expansions, pediatric updates, or new dosing guidance that increases clinician confidence

What are the patent and exclusivity fundamentals investors should anchor to?

For ALKINDI SPRINKLE, exclusivity value is commonly tied to:

• formulation patents (composition of matter or specific formulation),
• manufacturing process patents,
• method-of-use and pediatric use patents,
• any pediatric exclusivity extensions depending on the underlying regulatory pathway and timing.

Investment implication: the risk is not generic “hydrocortisone” in the abstract; the risk is generic substitution of the specific formulation and the speed with which payers shift coverage to alternatives.

How should investors position relative to the broader steroid market?

In systemic steroid replacement, the market’s structural characteristics shape investment positioning:

• Demand is not optional in adrenal insufficiency; it is therapeutic replacement.
• Therapeutic class competition is crowded in many geographies, increasing pricing scrutiny.
• Pediatric administration is a differentiator when it reduces medication errors and improves adherence.
• Net revenue is the decisive metric due to rebate structures and payer mix.

Relative value approach: ALKINDI SPRINKLE’s investment case is strongest when investors see:

• stable payer access,
• lower switching rates than alternatives,
• evidence of persistence advantages (refill continuity).

What are the key business and diligence questions for underwriting?

Even when the molecule is known, the economic story can differ by presentation. Underwriting diligence typically targets:

• Patient mix: percentage of covered patients with CAH vs other adrenal insufficiency etiologies
• Persistence: refill cadence and discontinuation rate
• Access friction: prior auth denial rates and time-to-coverage
• Net pricing: trend in gross-to-net with payer contracting shifts
• Competitive sensitivity: whether clinicians switch when alternative hydrocortisone products are preferred on formulary
• Operational stability: supply continuity, returns, complaint rates

Key Takeaways

• ALKINDI SPRINKLE is a pediatric hydrocortisone formulation where the investment case is driven by coverage durability, persistence, and payer net price, not by late-stage innovation risk.
• The core upside path is continued formulary wins and reduced access friction that increases treated patient share.
• The core downside path is formulation-level substitution and net price compression after competitive or exclusivity milestones.
• Investors should model three levers: share (starts), persistence (refills), and realized net pricing (gross-to-net).
• The diligence focus is on payer dynamics, supply stability, and competitive switching behavior, which determine whether chronic pediatric demand translates into durable revenue.

FAQs

1) What is ALKINDI SPRINKLE used for?

It is a hydrocortisone product used for pediatric adrenal insufficiency management, including congenital adrenal hyperplasia, under its approved indications.

2) Why does presentation matter for ALKINDI SPRINKLE’s economics?

In pediatric chronic therapy, ease of dosing and caregiver administration can reduce adherence issues and switching, supporting persistence and formulary stability.

3) What typically drives revenue for pediatric replacement steroids?

Prescription starts and treatment persistence, then net price realized after payer rebates and copay dynamics.

4) Where is the biggest competitive risk for ALKINDI SPRINKLE?

The risk is substitution to other hydrocortisone presentations or generics that win formulary position, especially after exclusivity windows tied to the specific formulation.

5) What should investors monitor to detect changing fundamentals early?

Formulary decisions, prior authorization trends, revenue-to-prescription ratios (pricing vs volume), and any supply interruptions or quality events.

---

References

[1] U.S. Food and Drug Administration. ALKINDI SPRINKLE prescribing information and related regulatory documents. FDA Drug Approval Reports and label repository.